Clinical Trials in Suwon, Gyeonggi-do
79 recruiting
Showing 1–20 of 63 trials
Recruiting
Phase 3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer444 enrolled285 locationsNCT06452277
Recruiting
Phase 3
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Regeneron Pharmaceuticals904 enrolled155 locationsNCT06091865
Recruiting
Phase 3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-Negative Breast Carcinoma+2 more
Olema Pharmaceuticals, Inc.1,000 enrolled150 locationsNCT07085767
Recruiting
Phase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals460 enrolled13 locationsNCT07357727
Recruiting
Phase 1Phase 2
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
HER2-Positive Solid Tumor
Yuhan Corporation147 enrolled19 locationsNCT05523947
Recruiting
AI ECG Algorithm for Detecting LV Systolic Dysfunction
HF - Heart Failure
Ajou University School of Medicine15,000 enrolled1 locationNCT07636759
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled618 locationsNCT07517263
Recruiting
Phase 2
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Breast CancerColorectal, CancerEsophageal Cancer+9 more
Jazz Pharmaceuticals200 enrolled28 locationsNCT06695845
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled74 locationsNCT07185997
Recruiting
Phase 3
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.500 enrolled246 locationsNCT06901531
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Solid TumorsHGGCancer Harboring BRAF Alterations+1 more
Fore Biotherapeutics254 enrolled70 locationsNCT05503797
Recruiting
Phase 3
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Immunoglobulin G4-Related Disease
Sanofi124 enrolled76 locationsNCT07190196
Recruiting
Phase 3
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
BioNTech SE621 enrolled202 locationsNCT06712355
Recruiting
Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Psoriatic Arthritis
Takeda1,088 enrolled189 locationsNCT06671483
Recruiting
Phase 3
Remibrutinib Open Label Roll-over Post-trial Access Protocol
Indication of the Parent Protocol
Novartis Pharmaceuticals212 enrolled7 locationsNCT07456891
Recruiting
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals44 enrolled10 locationsNCT05703516
Recruiting
Post Marketing Study on Pluvicto in Korea
Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals278 enrolled11 locationsNCT06514521
Recruiting
Phase 2
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 4
Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study
Heart FailureHeart Failure Due to Coronary Artery DiseaseValvular Cardiomyopathy
Kyungsub Song80 enrolled4 locationsNCT07572032
Recruiting
A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants
Arthritis, RheumatoidColitis Ulcerative
Eisai Korea Inc.2,040 enrolled65 locationsNCT06246123